Spectrum of histopathological diagnosis of lymph node biopsies and utility of immunohistochemistry in diagnosis of lymphoma: A 5 year retrospective study from a tertiary care Centre in South India

Shanmuga Priya S1, Rajalakshmi V2*

1Associate Professor, 2Professor, Dept. of Pathology, ESI Medical College & PGIMSR, Chennai, Tamil Nadu, India

**Abstract**

**Introduction:** The lymph node biopsy plays an important role in establishing the cause of lymphadenopathy. The distribution of lymphomas is varied in different geographic regions. The 2016 revision World Health Organization classification of lymphoid neoplasms is used to classify lymphomas.

**Aims:** To study retrospectively the spectrum of histopathological diagnosis in lymph nodes at our institution, diagnostic utility of immunohistochemical markers in the subtyping of both nodal and extranodal lymphomas and to correlate the histopathology and immunohistochemistry.

**Materials and Methods:** We retrospectively reviewed lymph nodes between 2012 and 2017, analysed the distribution of cases and classified lymphoma according to the revised 2016 World Health Organization classification of lymphoid neoplasms and compared with other studies.

**Results:** The distribution of various cases from 235 lymph nodes were as follows: 27% of granulomatous lymphadenitis, 25% of reactive lymphoid hyperplasia, 24% of metastatic deposit, 17% of lymphoma, and 7% of miscellaneous category that included progressive transformation of germinal centres, Kimuras disease, extramedullary hematopoiesis, kikuchi lymphadenitis, neuroendocrine tumor, schwannoma. B-cell lymphomas outnumbered T-cell lymphomas. The statistical parameters were compared between histopathology and immunohistochemistry. Sensitivity, specificity, diagnostic accuracy, positive predictive value and negative predictive value were calculated.

**Conclusions:** Lymph node biopsy helps in establishing the cause of lymph node enlargement. The distribution of lymphomas in India is varied when compared to the rest of the world. Immunohistochemistry plays an important role in subtyping lymphomas.

**Introduction**

Lymphadenopathy is a common clinical problem and biopsies confirm whether the etiology is neoplastic or non-neoplastic. The neoplastic disorders are mainly lymphohematogeneous and metastasis while non-neoplastic lesions are varied including infection, reactive changes and miscellaneous disorders like kikuchi Fugimoto disease, Kimura disease, progressive transformation of germinal centre, extramedullary hematopoiesis. Clinically lymphadenopathy can be peripheral or visceral. Lymphoma is a heterogeneous group of lymphoproliferative malignancies with clonal expansion of hematolymphoid cells that share the histologic pattern and immunohistochemistry of their normal counterpart. Diagnosis of lymphoid neoplasms has changed during the last three decades. The World Health Organization classification of tumors of hematopoietic and lymphoid tissues was published in 2001, updated in 2008 and revised in 2016. The revised 2016 WHO updates the current entities and facilitates the recognition of uncommon diseases thus having diagnostic, prognostic and therapeutic implications. In lymphoma panel there is no antibody that is specific and hence the interpretation is based on the panel and knowledge of particular antigen expression in normal, reactive and neoplastic conditions. Correct diagnosis and classification of lymphoma depends on the morphologic, immunophenotypic and molecular genetic features.

Current study was undertaken to evaluate the spectrum of histopathological diagnosis of lymph node biopsies, ascertain the frequency of Non-Hodgkin lymphoma subtypes and Hodgkin lymphoma subtypes in nodal and extranodal sites based on the WHO classification system by immunohistochemistry, the utility of immunohistochemical markers to subtype lymphomas and to correlate histopathology and immunohistochemistry findings.

**Materials and Methods**

A retrospective study of all lymph nodes received between 2012-2017 were studied and classified into infective, reactive, metastatic deposit, lymphoma and miscellaneous...
category that included progressive transformation of
germinal centres, Kimura disease, extramedullary
hematopoiesis, kikuchi lymphadenitis, neuroendocrine
tumor, schwannoma. A concise clinical history,
examination, and details of relevant investigations were also
obtained. These were helpful in reaching a probable clinical
diagnosis and formulations of the pathological diagnosis.
The data included 235 nodes and the sections were
processed using standard methods and stained with
Hematoxylin and Eosin stains. The panel of antibodies used
for immunohistochemistry included monoclonal antibody to
CD2, CD5, CD7, CD10, CD15, CD19, CD20, CD22, CD23,
CD30, CD45, CD45RO, CD56, Cd68, Cd117, Cd1a, bcl2,
bcl-6, cyclin-D1, Ki-67, Mum1, FoxP1, SOX11, Alk-1 and
polyclonal antibody to Cd3 and Tdt (Table 5). IHC was
performed according to avidin-biotin peroxide complex
method after pretreatment of antigen retrieval by heating in
microwave oven in 0.01M citrate buffer, PH 6.0. All
lymphomas were classified according to the standard World
health Organization classification of hematolymphoid
malignancies, 2016. Sensitivity, specificity, positive
predictive value, negative predictive value and diagnostic
accuracy were calculated using immunohistochemistry as
gold standard. We could assess the efficacy of
immunohistochemistry for categorization of lymphoma and
compare it with other studies (Table 4, 5). These statistical
parameters were compared between histopathological
parameters and immunohistochemistry. The statistical
analysis was done using Dx test software (Table 6).

Results
Two hundred and thirty five cases were studied and data
included 65 cases (27%) of granulomatous lymphadenitis,
58 cases (25%) of reactive lymphoid hyperplasia, 56 cases
(24% of metastatic deposit, 40 cases (17%) of lymphoma,
and 16 cases (7%) of miscellaneous (Table 1). Of 40 cases
of lymphoma, 27(68%) were non-Hodgkin lymphoma
(NHL) and 13 (32%) were Hodgkin lymphoma (HL) (Fig.
1, 2). Of 27 NHL cases 20 cases were nodal and the
remaining 7 were extranodal (Fig. 3, 4). B cell lymphomas
(22 cases; 81%) outnumbered T cell lymphoma (5 cases;
19%) (Fig. 5,6). Cervical nodes were the most common site
of biopsy (7 cases). The female to male ratio was 2.4:1
(Table 2). Majority of NHL were in 41-50 years of age
group followed by 51-60 years of age. The median age is 48
years. Distribution of lesions in female and male patients in
different age group and comparative study with other series
is shown in table 3, 4. The diagnostic accuracy of H&E was
91% with sensitivity of 92.9% and specificity of 50%. The
positive and negative predictive values were 97.5% and
25% respectively. Three cases did not correlate with
immunohistochemistry and the discordant cases were
kikuchi lymphadenitis, reactive lymphoid hyperplasia and
progressive transformation of germinal centres. Out of 13
cases of Hodgkins lymphoma classical type was the most
common subtype comprising 61% (8 cases) of cases of
which 6 were EBV positive and 2 EBV negative. It was
followed by 30% (4 cases) of nodular lymphocyte
predominant type of which 3cases were EBV positive and 1
EBV negative. There was one case of mixed cellularity
Hodgkin lymphoma that was EBV positive. Metastasis
constituted the remaining malignancies representing 24% of
total lymph node biopsies. Out of 56 cases of metastatic
lymphadenopathies, 22% (12 cases) were squamous cell
carcinoma, 66% (37 cases) were adenocarcinoma, 5% (3
cases)were poorly differentiated carcinoma, 5%(3 cases)
of papillary carcinoma thyroid and 2% (1 case) of small cell
carcinoma.

Table 1: Distribution of diagnosis in lymph nodes (n=235)

| S. No. | Diagnosis                        | Number of cases |
|-------|----------------------------------|-----------------|
| 1     | Granulomatous lymphadenitis       | 65              |
| 2     | Reactive lymphoid hyperplasia     | 58              |
| 3     | Metastatic deposit               | 56              |
| 4     | Lymphoma                         | 40              |
| 5     | Suppurative lymphadenitis         | 4               |
| 6     | Non-specific lymphadenitis        | 3               |
| 7     | Kimura disease                   | 2               |
| 8     | Progressive transformation of germinal centres | 1 |
| 9     | Extramedullary hematopoiesis      | 1               |
| 10    | Kikuchi lymphadenitis            | 3               |
| 11    | Schwannoma                       | 1               |
| 12    | Neuroendocrine tumor             | 1               |
Table 2: Demography of lymphomas

| Age (years) | Non-Hodgkin lymphoma (n=27) | Hodgkin lymphoma (n=13) |
|-------------|-----------------------------|-------------------------|
|             | Males | Females | Males | Females |
| <10         | 1     | 0       | 0     | 1       |
| 11-20       | 2     | 0       | 3     | 0       |
| 21-30       | 1     | 0       | 0     | 2       |
| 31-40       | 2     | 1       | 0     | 0       |
| 41-50       | 6     | 2       | 2     | 0       |
| 51-60       | 4     | 2       | 1     | 1       |
| 61-70       | 2     | 2       | 2     | 1       |
| 71-80       | 1     | 1       |       |         |

Table 3: Incidence of B-cell and T-cell lymphomas in various studies

| Diagnostic category | Present study | Rao A et al (2013) | Padhi S et al (2012) | Mushtaq S et al (2005) | Kalyan K et al (2006) | Naresh K N et al (2000) | Sharma M et al (2014) | Howell et al (2012) |
|---------------------|---------------|--------------------|----------------------|-----------------------|----------------------|------------------------|----------------------|---------------------|
| B cell lymphoma     | 81%           | 54%                | 96%                  | 86%                   | 72%                  | 79.1%                  | 89.3%                | 98%                 |
| T-cell lymphoma     | 19%           | 38%                | 4%                   | 24%                   | 67%                  | 16.2%                  | 10.7%                | 2%                  |

Table 4: Distribution of B-cell lymphomas in various studies

| Diagnostic category | Present study | Rao A et al (2013) | Padhi S et al (2012) | Mushtaq S et al (2005) | Kalyan K et al (2006) | Naresh K N et al (2000) | Sharma M et al (2014) | Howell et al (2012) |
|---------------------|---------------|--------------------|----------------------|-----------------------|----------------------|------------------------|----------------------|---------------------|
| DLBCL               | 56%           | 29.3%              | 69%                  | 76%                   | 26%                  | 34%                    | 46.8%                | 47%                 |
| FL                  | 21%           | 6.8%               | 8%                   | 6%                    | 4%                   | 12.6%                  | 12.8%                | 8%                  |
| MCL                 | 4%            | 4%                 | 5%                   | 4%                    | 3%                   | 3.4%                   | 17%                  | 5%                  |

Table 5: Immunohistochemical distinction between DLBCL and HL

| IHC markers | DLBCL          | HL              |
|-------------|----------------|-----------------|
| CD30        | +/-            | +(Uniform)      |
| CD15        |               | +               |
| Cd45        | +              | -               |
| PAX5        | +(strong)      | +(weak)         |
| CD20        | +(strong,uniform) | /+(weak)        |
| EBER        | -              | +               |
| OCT2/BOB1   | +              | -               |
| CD79a       | +              | -               |
| Bcl6        | -              | -               |
| P-63        | +              | -               |

Table 6: Point estimates and 95% confidence intervals

| Parameters                  | Point estimates (95% CI)     |
|-----------------------------|------------------------------|
| Sensitivity                 | 92.9% (80.5-98.5)            |
| Specificity                 | 50% (1.3-98.7)               |
| Positive predictive value   | 97.5% (86.8-99.9)            |
| Negative predictive value   | 25% (0.6-80.6)               |
| Positive likelihood ratio   | 1.857 (0.463-7.445)          |
| Negative likelihood ratio   | 0.143 (0.024-0.833)          |
| Odds ratio                  | 13 (0.641-263.815)           |
The present study showed granulomatous lymphadenitis was the most common cause of lymphadenopathy (27%) followed by reactive lymphoid hyperplasia (25%), metastatic deposit (24%), lymphoma (17%) and miscellaneous causes (7%). Lymphoma is a group of lymphoproliferative malignancies with distinct causes, patterns of behavior and responses to treatment. Approximately 30% of NHL arise from site other than lymph node, spleen or bone marrow. Site of localization and histologic type are the most important predictor of prognosis in extranodal lymphomas. Immunohistochemistry is useful and necessary diagnostic test that helps in subtyping different types of lymphoma. Age and gender are the risk factors for NHL and affect the treatment outcome of the disease and survival rate of patients. The occurrence of NHL is higher in men (worldwide age-standardised rate-ASR 6.1/100000) than women (ASR 4.2/100000). In our study also male to female ratio is 2.4:1. NHL is more common in older than young patients. In our study NHL was seen in age group 41-50 years (22%) followed by 51-60 years (15%). The median age in our study is 48 years. We compared our results with Rao et al. 1

---

**Fig. 1:** Chart depicting distribution of lymphomas

**Fig. 2:** Chart depicting extra nodal lymphomas

**Fig. 3:** Chart depicting subtypes of non-Hodgkin lymphoma in different nodes

**Fig. 4:** Chart depicting subtypes of non-Hodgkin lymphoma in extra nodal sit

**Fig. 5:** Microphotograph of Diffuse large B-Cell lymphoma (H&E x200)

**Fig. 6:** Microphotograph of tumor cells positive for CD20 (IHC x200)

**Discussion**

The present study showed granulomatous lymphadenitis was the most common cause of lymphadenopathy (27%) followed by reactive lymphoid hyperplasia (25%), metastatic deposit (24%), lymphoma (17%) and miscellaneous causes (7%). Lymphoma is a group of lymphoproliferative malignancies with distinct causes, patterns of behavior and responses to treatment. Approximately 30% of NHL arise from site other than lymph node, spleen or bone marrow. Site of localization and histologic type are the most important predictor of prognosis in extranodal lymphomas. Immunohistochemistry is useful and necessary diagnostic test that helps in subtyping different types of lymphoma. Age and gender are the risk factors for NHL and affect the treatment outcome of the disease and survival rate of patients. The occurrence of NHL is higher in men (worldwide age-standardised rate-ASR 6.1/100000) than women (ASR 4.2/100000). In our study also male to female ratio is 2.4:1. NHL is more common in older than young patients. In our study NHL was seen in age group 41-50 years (22%) followed by 51-60 years (15%). The median age in our study is 48 years. We compared our results with Rao et al. 1
Vallabhajosyula et al and Padhi et al (Table 4, 5). Rao et al reported 63.6% NHL occurred after 40 years of age with peak between 51-60 years. The median age of study population was 55.5 years in a study conducted by Vallabhajosyula et al. Padhi et al too reported the peak incidence during 4th to 5th decade. In our study B-cell lymphomas outnumbered T-cell lymphoma and the most common subtype being diffuse large B Cell lymphoma (DLBCL), followed by Follicular lymphoma, mantle cell lymphoma. We compared our results with Sharma et al, Rao et al, Kalyan et al, Padhi et al, Howell et al, Naresh et al and Mushtaq et al (Table 4,5). Out of 13 cases of Hodgkins lymphoma classical type was the most common subtype comprising 61% (8 cases) of cases of which 6 were EBV positive and 2 EBV negative. In our study, the diagnostic accuracy of H&E was 91% with sensitivity of 92.9% and specificity of 50%. The positive and negative predictive values were 97.5% and 25% respectively. Three cases did not correlate with immunohistochemistry and the discordant cases were kikuchi lymphadenitis, reactive lymphoid hyperplasia and progressive transformation of germinal centres.

Conclusion
Lymph node biopsy plays an important role in establishing the cause of lymphadenopathy. The distribution of lymphoma is varied and is comparable with the rest of the world. Age, gender and histologic subtype have prognostic and theranostic implications. Meticulous morphologic evaluation and a concise immunohistochemical panel is mandatory in subtyping nodal and extranodal lymphomas.

Future Studies
More cases need to be studied in future as the pathological and molecular heterogeneity of DLBCL has implications in molecular targeted and personalized therapy.

Acknowledgement
The authors are grateful to the technical staff of ESI medical college, Lister Metropolis for processing and staining the samples and to Aruna Patil for statistical analysis.

Conflict of Interest: None.

Source of Funding: None.

References
1. Roy A, Kar R, Basu D, Badhe BA. Spectrum of histopathologic diagnosis of lymph node biopsies: A descriptive study from a tertiary care center in South India over 5½ years. Indian J Pathol Microbiol 2013;56:103-8.
2. Swerdlov SH, Campo E, Pileri SA, Harris NL. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127(20):2375-90.
3. Vallabhajosyula S, Bajjal G, Vadhiraja B M, Fernandes DJ, Vidyasagar M S. Non-Hodgkin’s lymphoma: Is India ready to incorporate recent advances in day to day practice? J Can Res Ther 2010;6:36-40.
4. Padhi S, Paul TR, Challa S, Prayaga AK, Rajappa S, Raghunadharaa D et al., Primary Extra Nodal Non Hodgkin Lymphoma: A 5 Year Retrospective Analysis. Asian Pacific J Cancer Prev 2012:13(10):4889-95.
5. Sharma M, Mannan R, Madhuhar M, Navanis. Immunohistochemical analysis of non-Hodgkins lymphoma spectrum according to WHO-REAL classification: A single centre experience from Punjab, India. J Clin Diagn Res 2014;8(1):46-9.
6. Kalyan K, Basu D, Soundararaghavan J. Immunohistochemical typing of non- Hodgkin’s lymphoma-comparing working formulation and WHO classification. Indian J Pathol Microbiol 2006;49(2):203-7.
7. Howell JM, Auer-Greziski I, Zhang J, Andrews CN, Stewart D, Urbanski SJ. Increasing incidence rates, distribution and histological characteristics of primary gastrointestinal non- Hodgkin lymphoma in a North American population. Can J Gastroenterol 2012;26(7):452-6.
8. Naresh KN, Srinivvas V, Somam CS. Distribution of various subtypes of non-Hodgkin’s lymphoma in India: a study of 2773 lymphomas using R.E.A.L. and WHO Classifications. Ann Oncol 2000;11(Suppl 1):63-7.
9. Mushtaq S, Akhtar N, Jamil S, Mamoorn N, Khadim T, Sarfaraz T et al., Malignant lymphomas in Pakistan according to the WHO classification of lymphoid neoplasms. Asian Pac J Cancer Prev 2008;9(2):229-32.
10. Sengar M, Akhade A, Nair R, Menon H, Shet T, Gujal S, Sridhar E et al., A retrospective audit of clinicopathological attributes and treatment outcomes of adolescent and young adult non-Hodgkin lymphomas from a tertiary care center. Indian J Med Paediatr Oncol 2011;32:197-203.
11. Jegalain AG, Eberle FC, Pack SD. Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma. Blood 2011;118:2976–84.
12. Perry AM, Warnke RA, Hu Q. Indolent T-cell lymphoproliferative disease of the gastrointestinal tract. Blood 2013;122(22):3599-3606.
13. Swerdlov SH, Jaffe DS, Brousset P. International Lymphoma Study Group. Cytotoxic T-cell and NK-cell lymphomas: current questions and controversies. Am J Surg Pathol 2014;38(10):e50-71.
14. Cohen JJ, Kimura H, Nakamura S, Ko YH, Jaffe ES. Epstein-Barr virus-associated lymphoproliferative disease in nonimmunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008. Ann Oncol 2009;20(9):1472-82.
15. Kimura H, Ito Y, Kawabe S. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood 2012;119(3):673-86.
16. Nam-Cha SH, Montes-Moreno S, Salcedo MT, Sanjuan J, Garcia JF, Piris MA. Lymphocyte-rich classical Hodgkin’s lymphoma: distinctive tumor and microenvironment markers. Mod Pathol 2009;22(8):1006-15.
17. Dave SS, Fu K, Wright GW. Lymphoma/ Leukemia Molecular Profiling Project. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med 2006;354(23):2431-42.
18. Said J. The expanding spectrum of EBV1 lymphomas. Blood 2015;126(7):827-8.
19. Liu Q, Salaverria I, Pittaluga S. Follicular lymphomas in children and young adults: a comparison of the pediatric variant with usual follicular lymphoma. Am J Surg Pathol 2013;37(3):333-43.
20. Ciccone M, Agostinelli C, Rigolin GM, et al. Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays. Leukemia 2012;26(3):499-508.
21. Kim. Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma study group. *J Hematol Oncol* 2013;6:8.

22. Chan JK, Chan AC, Cheuk W. Type II enteropathy-associated T-cell lymphoma: a distinct aggressive lymphoma with frequent gd T-cell receptor expression. *Am J Surg Pathol* 2011;35(10):1557-69.

23. Vannata B, Zucca E. Primary extranodal B cell lymphoma: Current concepts and treatment strategies. *Chin Clin Oncol* 2015;4(1):10-7.

24. Boffetta P. Epidemiology of adult non-Hodgkin lymphoma. *Ann Oncol* 2011;22(suppl 4):27-31.

How to cite this article: Priya SS, Rajalakshmi V. Spectrum of histopathological diagnosis of lymph node biopsies and utility of immunohistochemistry in diagnosis of lymphoma: A 5 year retrospective study from a tertiary care Centre in South India. *Indian J Pathol Oncol* 2019;6(3):434-9.